 CAMBRIDGE, Mass.--BUSINESS WIRE--Alnylam Pharmaceuticals, Inc. Nasdaq: ALNY, the leading RNAi therapeutics company, announced today that the Company will present full 18-month results from the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of the polyneuropathy of hereditary transthyretin-mediated hATTR amyloidosis, at the Société Francophone du Nerf Périphérique SFNP Annual Meeting. The meeting will be held January 21-22 in Pa 